Business
AbCellera Reports Full Year 2022 Business Results
Total revenue of $485 million, compared to $375 million in FY 2021 Total cumulative partnered program starts of 101, with 23 new starts in the year Net
About this update from Abcellera Biologics Inc.
[{"type":"text","content":"\n\nTotal revenue of $485 million, compared to $375 million in FY 2021\n\n\nTotal cumulative partnered program starts of 101, with 23 new starts in the year\n\n\nNet earnings of $0.56 per share on a basic and $0.50 on a diluted basis, compared to earnings of $0.56 (basic) and $0.48 (diluted) per share in 2021\n\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) today announced financial results for the full year 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.\n\n“In 2022 we demonstrated strong topline results and ongoing success in our partnering business. Even more significant is the progress we made in scaling and expanding the capabilities of our engine during the year,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “We believe we are at an inflection point and expect to drive deeper value with partners and to prove our ability to consistently deliver clinical candidates for patients in need.”\n\nFY 2022 Business Summary\n\n\nEarned $485.4 million in total revenue.\n\n\nGenerated net income of $158.5 million, compared to net income of $153.5 million in 2021.\n\n\nReached a cumulative total of 174 programs under contract with 40 different partners.\n\n\nStarted discovery on 23 partnered programs, bringing the cumulative number of partnered program starts to 101.\n\n\nReporting the advancement of three additional molecules, taking the cumulative total to eight molecules in the clinic.\n\n\n\n\nKey Business Metrics\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nYear Ended December 31,\n\n\n\n \n\n\n\n \n\n\n\nChange\n\n\n\n\n\nCumulative Metrics\n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n2022\n\n\n\n \n\n\n\n%\n\n\n\n\n\nNumber of discovery partners\n\n\n\n \n\n\n\n \n\n\n\n36\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n40\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n11%\n\n\n\n\n\nPrograms under contract\n\n\n\n \n\n\n\n \n\n\n\n156\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n174\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n12%\n\n\n\n\n\nPartnered program starts\n\n\n\n \n\n\n\n \n\n\n\n78\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n101\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n29%\n\n\n\n\n\nMolecules in the clinic\n\n\n\n\n \n\n\n\n5\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n8\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n60%\n\n\n\n\nAbCellera added 18 partnered programs in 2022 to reach a cumulative total of 174 progra...